Analyst Research Report Snapshot

Title:

Peel Hunt: Clinigen (Buy) - A neat acquisition

Price:

$23.00

Provider:

Peel Hunt

Date:

31 Mar 2014

Pages:

3

Type:

AcrobatPDF

Companies referenced:

CLINC.L

Available for Immediate Download
Summary:

Clinigen (Buy) A neat acquisition Clinigen’s acquisition of Savene from SpePharm is a neat acquisition, making it unique in being the only company to hold full rights to dexrazoxane across both its approved indications. This should allow it to exploit marketing and supply chain synergies, giving it critical mass to roll out further geographies and perhaps line extensions. Savene fits very well into the portfolio and we see 6% EPS accretion from FY2015, moving our valuation up to 720p. Buy. Stefan.Hamill@peelhunt.com

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.